Art. -Nr.: HY-157214

NVS-STG2

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

NVS-STG2 is a molecular glue that targets STINGSTING by binding to pockets between adjacent STING dimer transmembrane domains, effectively acting as a molecular glue. NVS-STGI enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.76%
CAS. Nr.: 3030588-01-0
Formel: C₂₅H₃₃NO₅
Molecular Weight:427.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

NVS-STG2 Chemical Structure

CAS. Nr.: 3030588-01-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

NVS-STG2 (50 μM; 24 h) strongly induces ISRE-Luc reporter gene expression in a reporter gene assay in THP1-Dual cells, AC₅₀=5.2 μM^[1].
NVS-STG2 (50 μM; 16 h) induces STING-dependent IRF3 phosphorylation in a STING co-transfection reporter gene assay in HEK293T cells^[1].
NVS-STG2 (50 μM; 16 h) causes wild-type STING to form bright punctate structures in a STING translocation/aggregation assay in 293T cells, but not the R95A mutant^[1].
NVS-STG2 (40 μM; 16 h) induces the formation of higher-order oligomers of hSTING in native gel analysis of purified hSTING protein^[1].
NVS-STG2 (50 μM) induces high levels of IFNβ production in human peripheral blood mononuclear cells (PBMCs), comparable to cGAMP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HEK293T
Concentration:

50 μM
Incubation Time:

overnight
Result:

Induced STING-dependent IRF3 phosphorylation.

In Vivo

NVS-STG2 (800 μg; intratumoral injection; 3 times; days 11, 14, and 18) can significantly slow tumor growth in the MC38 tumor model of hSTING gene knock-in mice^[1].
NVS-STG2 (400 μg, 800 μg; intratumoral injection; 1 time; day 8) can induce significant dose-dependent T cell priming responses in the B16-SIY tumor model of hSTING gene knock-in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 wild-type and hSTING knock-in mice (10-12 weeks old, 20-25 g) with MC38 flank tumors and B16-SIY flank tumors^[1]
Dosage:

800 μg, 400 μg (not specified in the article about the solvent)
Administration:

For the MC38 tumor model, intratumoral injection, 3 times, on days 11, 14, and 18. For the B16-SIY tumor model, intratumoral injection, single dose, on day 8
Result:

In the MC38 tumor model, slowed tumor growth significantly, and resulted in no significant tumor growth among 4/9 mouse during the 33-day experimental period.
In the B16-SIY tumor model, exhibited a dose-dependent and significant induction of T-cell priming response. Resulted a significant increase in plasma IFNγ level at 6 h after dosing.

Chemical Information

CAS. Nr. 3030588-01-0
Appearance Solid
Molecular Weight 427.53
Formel C₂₅H₃₃NO₅
Color White to off-white
SMILES

COC1=C(C=CC(C(O)=O)=C1)NCC2=CC=C(C=C2)C3(OCC(C)(CO3)C)C(C)(C)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Immunity

A chemical agonist and the Golgi-resident lipid PI4P activate STING by inducing transmembrane helix rearrangement. [Abstract]

2025 Dec 5:S1074-7613(25)00506-0. PMID: 41352342

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (233.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3390 mL

11.6951 mL

23.3902 mL

5 mM

0.4678 mL

2.3390 mL

4.6780 mL

10 mM

0.2339 mL

1.1695 mL

2.3390 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.85 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.85 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (5.85 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li J et al. Activation of human STING by a molecular glue-like compound. Nat Chem Biol. 2023 Oct 12. [Content Brief]

[2]. Sulpizio A, et al. A new road to STING activation. Nat Chem Biol. 2023 Oct 13. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3390 mL	11.6951 mL	23.3902 mL	58.4754 mL
	5 mM	0.4678 mL	2.3390 mL	4.6780 mL	11.6951 mL
	10 mM	0.2339 mL	1.1695 mL	2.3390 mL	5.8475 mL
	15 mM	0.1559 mL	0.7797 mL	1.5593 mL	3.8984 mL
	20 mM	0.1170 mL	0.5848 mL	1.1695 mL	2.9238 mL
	25 mM	0.0936 mL	0.4678 mL	0.9356 mL	2.3390 mL
	30 mM	0.0780 mL	0.3898 mL	0.7797 mL	1.9492 mL
	40 mM	0.0585 mL	0.2924 mL	0.5848 mL	1.4619 mL
	50 mM	0.0468 mL	0.2339 mL	0.4678 mL	1.1695 mL
	60 mM	0.0390 mL	0.1949 mL	0.3898 mL	0.9746 mL
	80 mM	0.0292 mL	0.1462 mL	0.2924 mL	0.7309 mL
	100 mM	0.0234 mL	0.1170 mL	0.2339 mL	0.5848 mL

Keywords

NVS-STG2

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NVS-STG2

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Protein-protein Interaction Inhibitor Library

Molecular Glue Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NVS-STG2

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NVS-STG2

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Protein-protein Interaction Inhibitor Library

Molecular Glue Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NVS-STG2

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NVS-STG2 Related Classifications

HY-157214 Related Classifications